Interpretation of Chinese Pharmacopoeia 2020 Edition
[Friday , 12th Nov 2021]
Interpretation of Chinese Pharmacopoeia 2020 Edition
Qiaofeng Tao
If you have any question about this webinar, please contact us:
+86 (0)571 8710 3829

The Chinese Pharmacopoeia is the national statutory basis of guiding the development, production, operation, use, supervision, management of drug, etc.

In 1953, China promulgated the first edition of the Chinese Pharmacopoeia, and has maintained the pace of updating one version every five years since then. The Chinese Pharmacopoeia 2020 Edition was implemented since December 30, 2020, which overall improved quality standards for Chinese drugs, thus making a great difference on pharmaceutical manufacturers focused on APIs, excipients and packaging materials. For overseas companies concerned about the Chinese market, it is also necessary to keep abreast of:

What are the changes and features of the latest version of the Pharmacopoeia?

What are the remaining differences between the revised Chinese Pharmacopoeia and international drug standards?

To help international enterprises better understand the Chinese Pharmacopoeia 2020 Edition, Baipharm invited Ms. Qiaofeng Tao, Vice President of Zhejiang Institute for Food and Drug Control, to share her rich expertise and experience.   


1. National Drug Standard System of China

2. Overview of the Chinese Pharmacopoeia Commission and the Pharmacopoeia of the People’s Republic of China

3. Main Features of the Pharmacopoeia of the People’s Republic of China (2020 edition)

Qiaofeng Tao
Vice President
Ms. Tao Qiaofeng is a member of the 11th Chinese Pharmacopoeia Commission, the director of the Key Laboratory of Drug Microbiological Detection and Early Warning of the National Medical Products Administration, and a member of the Pharmaceutical Analysis Professional Committee of the Chinese Pharmaceutical Association. She is also the vice director of the Pharmaceutical Chemistry and Antibiotic Professional Committee of the Zhejiang Pharmaceutical Association, and the vice director of the Drug-Induced Disease Professional Committee of Zhejiang Provincial Pharmacological Society.